Microbial dial: How the gut microbiome tunes the severity of autism spectrum disorder

Abstract

A recent study used a monozygotic (MZ) twin design to investigate how the gut microbiome influences the severity of autism spectrum disorder (ASD) independent of genetic factors. By comparing genetically identical twins with discordant symptoms, the study identified the gut microbiome as a key non-shared environmental contributor. Beta-diversity analysis revealed distinct microbial community structures between high-severity and low-severity groups. Notably, the genus Porphyromonas, which is associated with inflammation and compromised gut barrier function, was enriched in high-severity twins. In contrast, these individuals exhibited reduced functional potential in pathways related to carbohydrate transport and amino acid metabolism. Collectively, these findings suggest that functional dysbiosis may exacerbate the symptoms of ASD via the gut-brain axis, potentially through systemic inflammation and altered metabolite production. While the MZ twin design effectively controls for genetic background, the study is limited by a small sample size and the absence of dietary data or mechanistic validation. Future research should employ multi-omics approaches and targeted interventions to confirm the regulatory chain of the gut microbiota metabolite-brain axis. Overall, the evidence suggests that while genetics provides the blueprint for ASD, the gut microbiome acts as a “dial” that modulates phenotypic severity.

Keywords: Autism spectrum disorder; Gut microbiota; Monozygotic twins; Microbiome-gut-brain axis; Butyrate-producing bacteria; Leaky gut; Probiotics

Core Tip: A recent study used monozygotic twins to decouple genetic factors from gut microbiome influences on the severity of autism spectrum disorder (ASD). Despite identical genomes, twins with higher symptom severity exhibited distinct microbial community structures, functional metabolic deficits, and enrichment of the pro-inflammatory Porphyromonas. These findings support that the microbiome is a primary driver of phenotypic heterogeneity in ASD. Although limited by a small, correlational sample, the study provides a critical foundation for identifying microbiome-based therapeutic targets. Collectively, the evidence reinforces the concept that while host genetics predispose individuals to ASD, the gut microbiome dictates the specific intensity of behavioral manifestations.